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Blepharophimosis syndrome (BPES), an autosomal dominant syndrome in which an eyelid malformation is asso-
ciated (type I) or not (type II) with premature ovarian failure (POF), has recently been ascribed to mutations in
FOXL2, a putative forkhead transcription factor gene. We previously reported 22 FOXL2 mutations and suggested
a preliminary genotype-phenotype correlation. Here, we describe 21 new FOXL2mutations (16 novel ones) through
sequencing of open reading frame, 5′ untranslated region, putative core promoter, and fluorescence in situ hybrid-
ization analysis. Our study shows the existence of two mutational hotspots: 30% of FOXL2 mutations lead to
polyalanine (poly-Ala) expansions, and 13% are a novel out-of-frame duplication. In addition, this is the first study
to demonstrate intra- and interfamilial phenotypic variability (both BPES types caused by the same mutation).
Furthermore, the present study allows a revision of the current genotype-phenotype correlation, since we found
exceptions to it. We assume that for predicted proteins with a truncation before the poly-Ala tract, the risk for
development of POF is high. For mutations leading to a truncated or extended protein containing an intact forkhead
and poly-Ala tract, no predictions are possible, since some of these mutations lead to both types of BPES, even
within the same family. Poly-Ala expansions may lead to BPES type II. For missense mutations, no correlations
can be made yet. Microdeletions are associated with mental retardation. We conclude that molecular testing may
be carefully used as a predictor for POF risk in a limited number of mutations.
Blepharophimosis-ptosis-epicanthus inversus syndrome
(BPES [MIM 110100]) is an autosomal dominant genetic
condition. In BPES type I, a complex eyelid malforma-
tion is associated with premature ovarian failure (POF),
whereas in BPES type II, only the eyelid defect is ob-
served (Zlotogora et al. 1983). Mutations in FOXL2
Received August 14, 2002; accepted for publication November 6,
2002; electronically published January 14, 2003.
Address for correspondence and reprints: Dr. Elfride De Baere, De-
partment of Medical Genetics, Ghent University Hospital, De Pinte-
laan 185, B-9000 Ghent, Belgium. E-mail: Elfride.DeBaere@rug.ac.be
 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7202-0030$15.00
(GenBank accession number AF301906), a putative
forkhead transcription factor gene located at 3q23
(MIM 605597), have recently been shown to cause both
types of BPES (Crisponi et al. 2001). Murine Foxl2
mRNA was found to be highly expressed in embryonic
mouse eyelids and in adult ovarian follicular cells (Cris-
poni et al. 2001). FOXL2 is the first human autosomal
gene shown to be implicated in ovarian maintenance. It
is a single-exon gene of 2.7 kb, and the predicted protein
of 376 amino acids belongs to the large family of fork-
head transcription factors, containing a 100-amino acid
DNA-binding forkhead domain and a polyalanine (poly-
Ala) tract of which the role has not yet been elucidated
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(Crisponi et al. 2001). Many members of the forkhead
gene family are known to be involved in different de-
velopmental processes, and eight of them have already
been shown to be implicated in human inherited devel-
opmental disorders (Carlsson and Mahlapuu 2002).
We described elsewhere the molecular characterization
of a translocation in a patient with BPES and reported
22 FOXL2 mutations (De Baere et al. 2000, 2001). We
and others have shown a preliminary genotype-pheno-
type correlation (Crisponi et al. 2001; De Baere et al.
2001): mutations resulting in a predicted truncated pro-
tein lead to type I BPES, whereas particular mutations
leading to an extended protein cause type II BPES. Fur-
thermore, we have assumed that FOXL2 haploinsuffi-
ciency may cause both types of BPES, suggested that
there may be phenotypic overlap between the two types
of BPES, and proposed that, in a fraction of patients
with BPES, the genetic defect does not reside within the
FOXL2 coding region and may be caused by a position
effect (De Baere et al. 2001).
Since FOXL2mutations have a pleiotropic effect, they
have been expected to play a role in nonsyndromic POF
(Crisponi et al. 2001; Prueitt and Zinn 2001). We an-
alyzed FOXL2 in 100 patients with isolated POF but,
so far, have not found causal mutations (De Baere et al.
2001, 2002). Recently, Harris et al. (2002) found two
FOXL2 variants with a presumed pathogenic effect in
2 of 70 patients with nonsyndromic POF.
In the present report, we describe 21 new FOXL2
mutations, of which 16 are novel ones. Our study shows
the existence of two mutational hotspots. In addition,
we demonstrate, for the first time, that the assignment
of an affected family to BPES type I or II is not always
possible, since we observed intra- and interfamilial phe-
notypic variability. Furthermore, we revise the current
genotype-phenotype correlation, since we found excep-
tions to it. We conclude that molecular testing may be
carefully used as a predictor for POF risk in a limited
number of mutations.
A total of 28 consenting probands—including affected
individuals from two families with type I BPES, four
families with type II, and one family in which both BPES
types were present, plus 15 individuals with sporadic
disease and patients from six families with BPES whose
BPES type we were unable to assess—were screened for
FOXL2 mutations. None of the probands have been
included in previous FOXL2 mutation studies. Patients
with BPES included in the present study presented with
blepharophimosis, ptosis, epicanthus inversus, and tele-
canthus. POF (in BPES type I) was defined as cessation
of menses for a duration of 6 mo at age !40 years and
an FSH concentration of 140 IU/liter. Patients with POF
underwent a clinical assessment that included taking a
complete medical and gynecological history and record-
ing age at onset of menses, menstrual history, and age
at menopause. A serum gonadotrophin assessment was
performed. In six families and in most patients with
sporadic disease, we were unable to assess the BPES type,
mainly because of the prepubertal age and lack of endo-
crinological/gynecological data in affected females and
because of an uninformative family history. All patients
had an apparently normal karyotype. PCR amplification
and sequencing of the FOXL2 coding region on genomic
DNAwas performed essentially as described byDeBaere
et al. (2001). For amplification and sequencing of the 5′
UTR and putative core promoter, we used the following
primers: FOXL2-promF 5′-CGGCAGCAAACGGCAG-
AGCAA-3′; FOXL2-promR 5′-GGAGCTCAGCCTCT-
GGCCAT-3′; FOXL2-promseqF 5′-GGCAGGCCGGT-
CCAGGCT-3′; FOXL2-promseqR 5′-GCTCCACC-
GAGTTCCGCTT-3′. Sequencing was carried out on an
ABI Prism 377 and 3100 sequencer (Applied Biosys-
tems). For FISH analysis, probes (RP11 BAC RP11-
54801, RPCI1 PACs 169-C10, 50-I6, 204-J22, 204-O7,
and 300-F16; UK-MRC) were labeled by standard nick-
translation, and FISH was performed as described else-
where (De Baere et al. 1999). When mutations were
found, we analyzed the segregation within the family for
familial cases and in both parents for sporadic cases, to
confirm the de novo nature of the mutation, whenever
possible.
New FOXL2 Mutations
In the present study, we found 21 FOXL2 mutations in
two families with BPES type I , four families with BPES
type II, one family with BPES with intrafamilial pheno-
typic variability, nine patients with sporadic disease, and
five families with BPES whose clinical type could not be
determined. Specifically, 2 are missense mutations, 1 is
a nonsense mutation, 12 are insertions or deletions lead-
ing to a frameshift, 5 are in-frame changes leading to
poly-Ala expansions, and 1 is a microdeletion. Sixteen
of them are novel. An overview of all FOXL2mutations
(53 in total, including those found in the current study)
and variants described so far, as well as relevant clinical
details, are given in table 1. None of the mutations found
in the present study were present in 200 normal control
chromosomes or in any of the unaffected family mem-
bers whom we analyzed. We have subdivided the FOXL2
mutations in classes, according to their effect on the
predicted protein (NCBI ORF finder). Groups A–D con-
tain the predicted truncated proteins: without forkhead
domain (group A), with partial forkhead domain (group
B), with complete forkhead domain and without poly-
Ala tract (group C), and with complete forkhead and
poly-Ala domains (group D). Group E comprises frame-
shift mutations that lead to elongated proteins with com-
plete forkhead and poly-Ala domains. Group F contains
in-frame changes, and group G contains missense mu-
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Table 1
Overview of All FOXL2 Mutations and Variants Described So Far, as Well as Relevant Clinical Details
Mutation
Group
and Numbera Effect Position Origin
BPES
Type Clinical Information
A: Truncation, no forkhead domain
1 Fs, truncated to 93 aa 290–291delCA GBb F1c BPES and POF in 32-year-old female (De Baere et al. 2001)
2 Q53X 394CrT CO F1 Two-generation BPES type I pedigree; affected females have POF (Ramirez-Castro et al. 2002)
B: Truncation, partial forkhead domain
3 Fs, truncated to 148 aa 404delC BE F BPES in 8-year-old male proband, prepubertal sister, and father (De Baere et al. 2001)
4 Y83X 486CrG US F BPES in 3-year-old female and father (De Baere et al. 2001)
5 Fs, truncated to 237 aa 568–569insT US F BPES in father and 2 daughters (no endocrinological data) (De Baere et al. 2001)
6 Fs, truncated to 229 aa 672–694del23 US S BPES in prepubertal female (no endocrinological data) (De Baere et al. 2001)
C: Truncation, complete forkhead
domain, no poly-Ala tract
7 F167X [737TrA;738CrA] Unknown S1 BPES in 21-year-old female showing growth retardation and delayed puberty at age 14 years. US: normal uterus and ovaries but no
follicles. Low serum estradiol levels, elevated serum LHd and FSHe levels. Received hormonal treatment, resulting in breast develop-
ment and regular menses. (Crisponi et al. 2001)
8 W204X 848GrA Unknown F1 Four-generation BPES type I pedigree (Crisponi et al. 2001)
9 Q219X 892CrT IT F1 Four-generation BPES type I pedigree (Amati et al. 1996; Crisponi et al. (2001)
CN F1 BPES, amblyopia, oligomenorrhea, and POF in affected females (De Baere et al. 2001)
D: Truncation, complete forkhead domain
and poly-Ala tract
10 Fs, truncated to 237 aa 945–946insC BE S BPES in 22-year-old male, sporadic (De Baere et al. 2001)
11 Fs, truncated to 373 aa 989–996del8 AU F1 Three-generation family with BPES type I; index patient had menarche at age 26 years, menstrual cycles for 12 mo, amenorrhea at age
27 years (fig. 2, D11) (current study)
12 Y274X 1059CrG BE F12 Mother transmits BPES to daughter: oligomenorrhea at age 31 years, amenorrhea at age 32 years (low serum estradiol/progesterone and
elevated serum LH and FSH levels; US: normal uterus/ovaries, secondary sex characteristics normal), ovum donation at age 33 years,
resulting in one successful pregnancy (fig. 2, D12) (current study)
13 Fs, truncated to 360 aa 1080–1096dup17 BE S BPES in 8-year-old male, sporadic, de novo (current study)
BE F2 Affected mother transmits BPES to son (stenosis of lacrimal ducts and intestinal malrotation) (fig. 2, D13) (current study)
BE S BPES in 5-year-old female, sporadic (current study)
NO S BPES in 1-year-old female, sporadic, de novo (current study)
GB F Two-generation BPES pedigree, type unknown (fig. 2, D13) (current study)
AU F BPES in family of unknown type (male-to-male transmission; fig. 2, D13) (current study)
DE F Two-generation BPES pedigree, type unknown (fig. 2, D13) (current study)
14 Fs, truncated to 360 aa 1092–1108dup17 Unknown F1 Four-generation BPES type I pedigree (Crisponi et al. 2001)
15 Fs, truncated to 357 aa 1149–1156dup8 GB F1 Four-generation BPES type I pedigree (Harrar et al. 1995; De Baere et al. 2001) (repeated in Bell et al. 2001)
16 Fs, truncated to 354 aa 1163delC BE S BPES in 5-year-old female, sporadic (current study)
E: Elongation with complete forkhead
domain and poly-Ala tract
17 Fs, extended to 532 aa 1041–1042insC GB F2 BPES in mother and 2 daughters (De Baere et al. 2001)
GB F Three-generation family with BPES of unknown type (Harrar et al. 1995; De Baere et al. 2001) (repeated in Bell et al. 2001)
(dup1036Cp
1041–1042insC)
JP S BPES in 12-year-old female, sporadic (Kosaki et al. (2002)
MX F1 II:4 (fig. 2, E17) with oligomenorrhea at age 17 years, secondary amenorrhea at age 29 years (low estradiol and progesterone, elevated
FSH and LH, atrophic ovaries on US, primordial follicles on ovarian biopsy, and normal secondary sex characteristics); received ovum
donation at age 34 years. Two other affected sisters have POF. II:14 (fig. 2, E17) oligomenorrhea at age 17 years, secondary amenor-
rhea at age 22 years (current study)
18 Fs, extended to 526 aa 1092–1108del17 JP F2 BPES in 5-year-old female, 38-year-old father, 71-year-old grandfather, and 74-year-old paternal grandaunt (who has 3 children) (Ya-
mada et al. 2001)
19 Fs, extended to 532 aa 1164–1165insA BE S BPES in 3-year-old female (no endocrinological data) (De Baere et al. 2001)
20 Fs, extended to 449 aa 1335delG US S BPES in male patient (De Baere et al. 2001)
21 Fs, extended to 532 aa 1366–1367insT NL S BPES in 1-year-old female patient, de novo (current study)
DE F Three-generation BPES pedigree, unknown type (fig. 2, E21) (current study)
F: In-frame mutation
22 I85del, 375 aa 490–492delATC BE S BPES in 6-year-old female patient (no endocrinological data) (De Baere et al. (2001)
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23 60–64dup5 415–429dup15 BE F2 Affected mother (oligomenorrhea and heavy menses) transmits BPES to son (De Baere et al. 2001)
24 [224–225del2;225–234dup10] [909–911delAGC;
912–938dup27]
US F2 Four-generation BPES type II pedigree. Fertility problems in 2 affected females, of whom 1 gave premature birth to 2 babies who lived
only a few days, and another had a pregnancy after fertility treatment, respectively (De Baere et al. 2001)
25 224–234dup10 909–938dup30 Unknown F2 Five-generation BPES type II pedigree, affected females transmit disease (Crisponi et al. 2001)
Unknown F2 Two-generation family with BPES type II, affected mother transmits BPES to daughter (Crisponi et al. 2001)
Unknown S BPES in male, sporadic, de novo (Crisponi et al. 2001)
US F2 Four-generation family with BPES type II (Small et al. 1995; De Baere et al. 2001)
IT S BPES in 5-year-old male patient (De Baere et al. 2001)
US S BPES in 17-year-old female patient (no endocrinological data) (De Baere et al. 2001)
CO F2 Three-generation BPES type II pedigree. Affected female transmits disease (Ramirez-Castro et al. 2002)
CO F2 Three-generation BPES type II pedigree. Affected female transmits disease (Ramirez-Castro et al. 2002)
DE F2 Three-generation BPES type II pedigree (fig. 2, F25) (current study)
BE F Two-generation BPES pedigree (male-to-male transmission; fig. 2, F25) (current study)
FR S BPES in 10-year-old female, sporadic, de novo (current study)
26 221–231dup10 900–929dup30 US F2 BPES 25-year-old female proband and mother (De Baere et al. 2001)
BE S BPES in 23-year-old male patient (De Baere et al. 2001)
BE S BPES in 8-year-old male patient, sporadic (current study)
27 228–232trip5 921–935trip15 AU F2 Three-generation BPES type II pedigree (fig. 2, F27) (current study)
G: Missense
28 L106F 553CrT ZA S BPES in 1-year-old male patient, de novo (current study)
29 N109K 564CrA AU F2 Five-generation BPES type II pedigree (fig. 2, G29) (current study)
30 S217F 887CrT BE F BPES in father and 2 prepubertal daughters (no endocrinological data) (De Baere et al. 2001)
H: Cytogenetic rearrangement
31 t(3;21)(q23;q22.1) 5′ to FOXL2 US S BPES, no associated symptoms (Praphanphoj et al. 2000)
32 t(3;4)(q23;p15) BPESC1 gene, 5′ to FOXL2 JP S BPES, no associated symptoms (Fukushima et al. 1991; De Baere et al. 2000)
33 t(3;7)(q23;q32) C3orf5 gene, 5′ to FOXL2 IT S BPES, no associated symptoms (Boccone et al. 1994; Crisponi et al. 2001)
34 Microdeletion FOXL2 and other genes DK F BPES and mental retardation in father and prepubertal 7-year-old daughter (De Baere et al. 2001)
35 Microdeletion FOXL2 and other genes FI S BPES in 9-year-old male, mentally retarded, abnormally rotated ears, flat and broad nose bridge, scoliosis, high-arched palate, and
umbilical hernia (current study)
I: Variant ORFf
F167F 738CrT Mix NA 12/140 (8.6%) POF, 4/46 (8.7%) XX male, 2/110 (1.8%) control chromg (De Baere et al. 2002)
SI, NZ NA 5/140 (3.6%) POF chrom, 9/200 (4.5%) control chrom (Harris et al. 2002)
BE S BPES in 6-year-old female, sporadic (homozygous) (current study)
G174G 759CrT Mix NA 1/140 (0.7%) POF, 1/46 (2.2%) XX male, 0/110 control chrom (De Baere et al. 2002)
A179G 773CrG SI, NZ NA 5/140 (3.6%) POF chrom, 9/200 (4.5%) control chrom (Harris et al. 2002)
BE S BPES in 6-year-old female, sporadic (homozygous) (current study)
G187D 797GrA Unknown NA 1/46 (2.2%) XX male chrom; also present in unaffected family members (De Baere et al. 2002)
221–230del10 898–927del30 SI NA 1/140 (0.7%) POF, 0/200 control chrom (Harris et al. 2002)
Y258N 1009TrA NZ NA 1/140 (0.7%) POF, 0/200 control chrom (Harris et al. 2002)
P285S 1090CrT Unknown NA 1/46 (2.2%) XX male chrom, 0/110 control chrom (De Baere et al. 2002)
P286P 1095TrG Mix NA 3/140 (2.1%) POF, 3/46 (6.5%) XX male, 0/110 control chrom (De Baere et al. 2002)
SI, NZ NA 3/140 (2.1%) POF chrom (Harris et al. 2002)
A301A 1140GrT Unknown NA 1/140 (0.7%) POF, 0/110 control chrom (De Baere et al. 2002)
A369A 1344GrT Unknown NA 1/46 (2.2%) XX male, 0/110 control chrom (De Baere et al. 2002)
Variant putative core promoter:
Effect unknown 317GrC RU S Variant in typical patient with BPES, unaffected father and sister (current study)
Effect unknown 104GrA DE F Variant in 5-year-old male patient with BPES, causal mutation found in ORF (current study)
NOTE.—The mutations representing the two mutational hotspots demonstrated in the present study are boxed.
a Numbering according to Crisponi et al. (2001).
b AU p Australia; BE p Belgium; CN p China; CO p Colombia; FR p France; DE p Germany; DK p Denmark; FI p Finland; GB p United Kingdom; IT p Italy; JP p Japan; MX p Mexico; NL p The Netherlands; NOp Norway;
NZ p New Zealand; RU p Russian Federation; SI p Slovenia; US p United States; ZA p South-Africa
c fs p frameshift; US p ultrasound; F1 p familial, type I; F2 p familial, type II; F12 p familial, intrafamilial phenotypic variability; F p familial, type undetermined; S1 p sporadic, type I; S p sporadic; NA p not applicable.
d LH p luteinizing hormone.
e FSH p follicle-stimulating hormone.
f ORF p open reading frame.
g chrom p chromosomes.
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tations. Group H comprises the cytogenetic rearrange-
ments. Variants are included in group I. Figure 1 rep-
resents the predicted proteins of all FOXL2 mutations
in the ORF reported so far. In figure 2, all relevant ped-
igrees are shown.
The first series of mutations found in the present study
belongs to the group of the predicted truncated proteins
with complete forkhead and poly-Ala domains (groupD)
(table 1; fig. 1, translations 10–16). Of particular interest
is the novel and unique mutation 1059CrG (Y274X)
found in a family in which a mother affected by BPES
type II transmitted the disease to her daughter, affected
by BPES type I. The latter received ovum donation at
age 33 years, resulting in one successful pregnancy (fig.
2, D12). This is the first reported case in which the
occurrence of both types of BPES in the same family
caused by the same mutation is clearly documented (in-
trafamilial phenotypic variability).
The second series of new mutations belongs to the
group of predicted elongated proteins with complete
forkhead and poly-Ala domains (group E) (table 1; fig.
1, protein translations 17–21). It is interesting that the
recurrent insertion 1041–1042insC, which was previ-
ously found in one family with type II BPES, one family
of unknown type, and a patient with sporadic disease
(De Baere et al. 2001; Kosaki et al. 2002), was found
here in a family with type I BPES, in which one of the
affected females received ovum donation (fig. 2, E17).
This is the first mutation shown to lead to both BPES
types in different families (interfamilial phenotypic
variability).
The third series of new mutations belongs to the
group of in-frame changes (group F) (table 1; fig. 1,
protein translations 22–27). It is notable that we found,
in a family with BPES type II, a novel in-frame 15-bp
triplication 921–935trip15, leading to a poly-Ala ex-
pansion 228–232trip5 (fig. 2, F-27). This is the first
triplication observed in the poly-Ala tract of FOXL2.
It may be explained by a replication error, further sug-
gesting that DNA hairpin–induced polymerase slippage
is the most probable mechanism underlying in-frame
changes in the poly-Ala tract of FOXL2 (hypothesis
outlined in fig. 3), as we suggested elsewhere (De Baere
et al. 2001).
The fourth series of mutations belongs to the group
of missense changes (group G) (table 1; fig. 1, protein
translations 28–30). In amale patient with sporadic BPES
and a male patient from a family with BPES type II (fig.
2, G-29), we found a transition 553CrT (L106F) and
a transversion 564CrA (N109K), respectively. Both
missense mutations are novel, unique, and the first ones
reported in the forkhead domain. The absence of L106F
in the unaffected parents, the drastic amino acid change
(asparagine to lysine) in N109K, and the absence of the
mutations in 200 control chromosomes are suggestive
of a pathogenic effect of both mutations. In addition,
leucine at position 106 and asparagine at position 109
are both conserved in 24 forkhead domains of human
genes (Crisponi et al. 2001) and in four orthologous
genes (mouse, rat, goat, and pufferfish) (Cocquet et al.
2002).
Furthermore, we identified a microdeletion (groupH)
in a male patient with sporadic BPES, mental retarda-
tion, and other associated symptoms. FISH analysis, us-
ing probes from the BPES region at 3q23, showed a het-
erozygous deletion in 100% of the mitoses studied (50
per probe) (data not shown). The microdeletion, esti-
mated to be at least 200 kb, contains several known
genes: FOXL2, C3orf5 (Crisponi et al. 2001), BPESC1
(De Baere et al. 2000), RBP1, RBP2, b′-COP (De Baere
et al. 1999), and other as-yet-unidentified genes. Fur-
thermore, it contains the human counterpart of an 11.7-
kb deletion, identified in the polled intersex (PIS) goat
and known to contain elements controlling the expres-
sion of several genes of that region (Schibler et al. 2000;
Pailhoux et al. 2001). The fine mapping of the extent
of this and other microdeletions will be the subject of
further studies. Polymorphic and unclassified variants
(group I) have been shown in table 1.
Finally, we were unable to find a causal mutation in
one family with BPES of unknown type and in six spo-
radic BPES cases using the current strategy. This may
be explained by a misdiagnosis in some cases, by a total
gene deletion, or by a defect residing outside the tran-
scription unit (position effect), which may be missed
through the current screening method. Further attempts
are under way to elucidate the molecular defects in these
patients.
Spectrum of FOXL2 Mutations
Forty-seven percent (25/53) of all FOXL2 mutations re-
ported so far in the ORF are changes leading to a frame-
shift. Thirty-four percent (18/53) are in-frame changes,
of which the majority lead to poly-Ala expansions (16/
53). Thirteen percent (7/53) are nonsensemutations, and
6% (3/53) are missense mutations, of which two are
located in the forkhead domain (fig. 1). In addition, two
microdeletions containing FOXL2 and other genes were
found in patients with BPES, as were three balanced
translocations, which were located !200 kb 5′ of FOXL2
and exerted a position effect (table 1).
Polyalanine Expansions
The present study further confirms the existence of a
mutational hotspot in the region coding for the poly-
Ala domain, since 30% of all mutations in the ORF lead
to poly-Ala expansions, resulting mainly in BPES type
II (fig. 1; table 1). There are at least six other genes in
Figure 1 The predicted protein translations for FOXL2 mutations detected in this and previous studies are shown at the left and are assembled into groups. Groups A–D are predicted truncated
proteins: A, without forkhead domain; B, with partial forkhead; C, with complete forkhead and without poly-Ala tract;D, with complete forkhead and poly-Ala domains. Group E comprises frameshift
mutations leading to elongated proteins with complete forkhead and poly-Ala domains; group F, in-frame mutations; and group G, missense mutations. Vertical stripes indicate the forkhead domain,
dark gray shows the poly-Ala tract, and diagonal stripes represent novel amino acids caused by a frameshift mutation. In the first column, the corresponding nucleotide changes are represented. The
numbering is according to Crisponi et al. (2001). Mutations found in the present study are indicated in bold, and novel mutations are underlined. In the second column, the respective amino acid
changes are shown. The two mutational hotspots demonstrated in the present study are boxed, and their percentages are shown at the right: 30% of the mutations lead to poly-Ala expansions, and
13% are a novel duplication 1080–1096dup17. Abbreviations: fs p frameshift; stop p stop codon. In the third column, the BPES type is shown (F1 p familial, type I; F2 p familial, type II; F12
p familial, occurrence of both BPES types in the same family; F p familial, type undetermined; S1 p sporadic, type I; and S p sporadic).
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Figure 2 Pedigrees and respective FOXL2 mutations of patients with familial BPES, represented in accordance with the subdivision and
numbering of figure 1. For patients with sporadic disease, no pedigree information is shown. Affected individuals are indicated by filled symbols;
individuals tested are indicated by an asterisk below the symbol. SIDS p sudden infant death syndrome. Abbreviations: AU p Australia; BE
p Belgium; DE p Germany; GB p United Kingdom; MX p Mexico.
which stable poly-Ala expansions exceeding a critical
number have been shown to cause human disease: mu-
tations of HOXD13 in synpolydactyly (MIM 142989),
of RUNX2 in cleidocranial dysplasia (MIM 600211), of
PABP2 in oculopharyngeal muscular dystrophy (MIM
164300), ofZIC2 in holoprosencephaly (MIM603073),
of HOXA13 in hand-foot-genital syndrome (MIM
142959), and of ARX in X-linked mental retardation
(MIM 300382) (Stromme et al. 2002). Although the
mutational mechanisms may differ, the net result (ad-
dition of 1–10 extra alanine residues) is the same. So
far, the role of the poly-Ala tract in FOXL2 has not yet
been elucidated. However, the number of alanine residues
(i.e., 14) is strictly conserved among the human, mouse,
rat, and goat, suggesting the existence of strong func-
tional or structural constraints (Cocquet et al. 2002). In
several transcription factors, alanine-rich regions, which
form a-helices, were found to be responsible for re-
pression of target genes (Han and Manley 1993). In-
deed, computer-assisted secondary structure predic-
tions (nnPredict-UCSF) suggest that the poly-Ala tract
of FOXL2 consists of an a-helical region (data not
shown). The poly-Ala expansions observed in FOXL2
either may directly interfere with protein-protein inter-
actions or may distort an essential secondary structure.
To elucidate the true effect of the poly-Ala expansion
on FOXL2, further studies are required.
Other Recurrent Mutations
Apart from poly-Ala expansions, we found a novel du-
plication 1080–1096dup17 in seven families (13% of all
mutations in the ORF reported so far). This duplication
occurs de novo in patients with sporadic disease and in
unrelated families of heterogeneous ethnic origins (table
1), suggesting an independent origin and representing a
second mutational hotspot. Other recurrent mutations
are 892CrT (Q219X), found in families of Italian and
Chinese origin with BPES type I (table 1). The insertion
1041–1042insC was found in four unrelated families,
including a patient with sporadic disease (table 1). Fi-
nally, an insertion in the stop codon 1366–1367insTwas
found twice, de novo in a patient with sporadic disease
and in a family (table 1). These data suggest that the last
three mutations also have an independent origin.
Reports 485
Figure 3 Explanation of the mechanism of the novel triplication
921–935trip15 by a replication error. Predictions of DNA hairpins are
based on MFOLD (Walter et al. 1994). When the DNA polymerase
is stalling because of the GC richness of the region, the sequences 1
and 2 of the newly synthesized strand form a DNA hairpin because
they are self-complementary (structure 1). This allows the sequence 3
to hybridize with the template of the region 2, since they have exactly
the same sequence, and this leads to a duplication of the underlined
sequence (nt 921–935). Once this extra sequence is present (4), there
may be a rearrangement of the hairpin, which leads to the formation
of another one involving the sequences (single and double asterisk).
The formation of the second hairpin is favorable, because it is more
stable (by an energy excess of 1.5 kcal/mole; see structure 2). Finally,
the 3′ end of the sequence 4 hybridizes with the template of sequence
2, which results in the triplication after escaping repair. Further, notice
that sequences 1–4 form a very stable, almost perfect, hairpin (28
kcal/mole).
Intra- and Interfamilial Phenotypic Variability
Elsewhere, we described menstrual abnormalities and
reduced female fertility in two families with BPES type
II, suggesting phenotypic overlap between both BPES
types (De Baere et al. 2001). Bell et al. (2001) described
a family with BPES type I in which the first generations
of affected females are infertile and three affected young
women in the youngest generation have normal pelvic
ultrasound and hormone levels, suggestive of phenotypic
variability. However, in this family, early age of the af-
fected women may preclude accurate prediction of their
ovarian phenotypic outcome, on the basis of these test
results, since the onset of POF usually occurs at a later
age.
In the present study, we show, for the first time, fam-
ilies with clear intra- and interfamilial phenotypic var-
iability caused by the same mutation (number 12 and
17, respectively, in table 1 and fig. 1). Phenotypic var-
iability is an important item for genetic counseling, be-
cause parents considering reproduction would like to
know how severely affected a child will be. Variability
may be caused by a combination of the effects of “mod-
ifier” genes and the environment (modulating the se-
verity of POF or the age at onset). Haploinsufficient
conditions are especially sensitive to such effects (Veitia
2002).
Revised Genotype-Phenotype Correlation
To add novel insights to the genotype-phenotype cor-
relation demonstrated by us and others (Crisponi et al.
2001; De Baere et al. 2001), we revised genotypes and
phenotypes of this and previous studies. The establish-
ment of a reliable genotype-phenotype correlation pro-
vides challenges for genetic counseling, since molecular
testing may allow prediction of the development of POF.
We observe that mutations leading to predicted trun-
cated proteins without forkhead domain (group A), or
with complete forkhead domain but without poly-Ala
tract (group C), lead almost certainly to BPES type I.
Mutations of group A are supposed to lead to haploin-
sufficiency of FOXL2, since DNA-binding activity is
abolished because of disruption of the forkhead domain.
Although, in general, nonsense- or frameshift-mutated
transcripts are degraded by nonsense-mediated decay
(NMD), intronless genes may be insensitive to NMD (as
reported for the melanocortin 4-receptor gene; Brocke
et al. 2002). The intronless FOXL2 gene might there-
fore be NMD insensitive, giving rise to stable mutated
transcripts and expressed mutated proteins. For none
of the mutations that lead to predicted proteins with
partial forkhead domain (group B) can a correlation be
made, because of lack of informative families.
Nonsense mutation 1059CrG (Y274X) (fig. 1, trans-
lation 12), which belongs to the group of predicted trun-
cated proteins with complete forkhead and poly-Ala
domains (group D), leads to intrafamilial phenotypic
variability, whereas 1080–1096dup17 (fig. 1, translation
13) occurs in patients with BPES of unknown type and,
surprisingly, also in a pedigree with BPES type II. Taken
together, these two truncating mutations of group D
lead to a BPES phenotype that would not have been
expected on the basis of the previous genotype-phe-
notype correlation, not accounting for interindividual
variability.
Another mutation 1041–1042insC (fig. 1, translation
17), which belongs to the group of predicted elongated
proteins with complete forkhead and poly-Ala domain
(group E) leads, surprisingly, to BPES type I and to BPES
type II in different families. This is the third mutation
that is not in line with the previously suggested geno-
type-phenotype correlation and is the second mutation
found to lead to both types of BPES, although not in
the same family (interfamilial phenotypic variability).
In-frame mutations 909–938dup30, 900–929dup30,
and 921–935trip15 (fig. 1, translation 25, 1–26, and
1–27, respectively), which belong to group F and lead
to poly-Ala expansions, occur in families with BPES of
unknown type and in families with BPES type II. So far,
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we can conclude that poly-Ala expansions most likely
lead to BPES type II and may allow childbearing.
Missense mutation 564CrA (N109K) of group G
leads to BPES type II (fig. 1, 29), whereas, for the other
ones, no correlations can be made. The microdeletions
in group H occur in patients with sporadic or familial
BPES, with mental retardation as a major associated
feature.
In conclusion, we assume that for predicted proteins
with a truncation before the poly-Ala tract, the risk for
development of POF is high. For mutations that lead
to a predicted truncated or extended protein containing
an intact forkhead and poly-Ala tract, no clear-cut pre-
dictions are possible so far, since such mutations may
lead to the two types of BPES (even within the same
family). Moreover, our data strongly suggest that poly-
Ala expansions lead to BPES type II. For missense mu-
tations, no predictions can be made yet, because of the
small number and lack of informative families. Micro-
deletions lead to a contiguous gene syndrome, including
mental retardation, but in most cases, that is already
diagnosed before molecular analyses. Finally, we con-
clude that molecular testing may be carefully used as a
predictor for POF risk in a limited number of mutations.
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